ESSA Pharma IncNASDAQ:EPIX
- LAST PRICE6.8800
- TODAY'S CHANGE (%)-0.0700 (-1.0072%)
- Bid / Lots6.7800/ 2
- Ask / Lots8.2500/ 2
- Open / Previous Close7.0300 / 6.9500
- Day Range
- 52 Week Range
- Volume13,725
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EPIX |
|---|---|---|
| 09:32 ET | 1447 | 7.19 |
| 09:52 ET | 120 | 7.3304 |
| 09:54 ET | 500 | 7.15 |
| 10:21 ET | 416 | 7.1499 |
| 10:24 ET | 140 | 7.1484 |
| 10:35 ET | 100 | 7.12 |
| 10:55 ET | 100 | 7.02 |
| 11:13 ET | 200 | 7.01 |
| 11:15 ET | 1200 | 6.875 |
| 11:22 ET | 100 | 6.905 |
| 11:26 ET | 757 | 6.96 |
| 11:47 ET | 100 | 6.8912 |
| 12:02 ET | 100 | 6.8905 |
| 12:12 ET | 100 | 6.89 |
| 12:23 ET | 100 | 6.885 |
| 01:14 ET | 100 | 6.985 |
| 01:37 ET | 100 | 6.885 |
| 01:39 ET | 100 | 6.89 |
| 02:06 ET | 100 | 6.855 |
| 02:11 ET | 100 | 6.87 |
| 02:13 ET | 165 | 6.86 |
| 02:33 ET | 100 | 6.82 |
| 02:42 ET | 100 | 6.81 |
| 02:56 ET | 100 | 6.925 |
| 03:03 ET | 100 | 6.815 |
| 03:30 ET | 100 | 6.74 |
| 03:50 ET | 100 | 6.78 |
| 03:52 ET | 200 | 6.78 |
| 03:57 ET | 1044 | 6.9386 |
| 03:59 ET | 721 | 6.88 |
Apr 9, 2024
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ESSA Pharma Inc | 304.4M | -11.8x | --- |
Inovio Pharmaceuticals Inc | 306.5M | -2.0x | --- |
Q32 Bio Inc | 305.3M | -0.7x | --- |
Fractyl Health Inc | 311.7M | -3.3x | --- |
Acrivon Therapeutics Inc | 296.1M | -3.5x | --- |
Zura Bio Ltd | 294.2M | -1.1x | --- |
Company Information
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Contact Information
- Headquarters
- 999 West Broadway, Suite 720VANCOUVER, BC, Canada V5Z 1K5
- Phone
- 778-331-0962
- Fax
- 778-331-0962
Executives
- Non-Executive Independent Chairman of the Board
- Richard Glickman
- President, Chief Executive Officer, Director
- David Parkinson
- Chief Financial Officer
- David Wood
- Chief Operating Officer, Executive Vice President
- Peter Virsik
- Executive Vice President, Chief Medical Officer
- Alessandra Cesano
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $304.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-0.59 |
Book Value | $3.30 |
P/E Ratio | -11.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
